The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria - 07/03/18
Doi : 10.1016/j.jaci.2017.10.018
Marcus Maurer, MD a 
, Allen Kaplan, MD b, Karin Rosén, MD, PhD c, Michael Holden, MD, MS c, Ahmar Iqbal, MD c, Benjamin L. Trzaskoma, MS c, Ming Yang, PhD c, Thomas B. Casale, MD d
, Allen Kaplan, MD b, Karin Rosén, MD, PhD c, Michael Holden, MD, MS c, Ahmar Iqbal, MD c, Benjamin L. Trzaskoma, MS c, Ming Yang, PhD c, Thomas B. Casale, MD d a Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité–Universitätsmedizin Berlin, Berlin, Germany
b Medical University of South Carolina, Charleston, SC
c Genentech, Inc, South San Francisco, Calif
d University of South Florida, Tampa, Fla
| This study was funded by Genentech, Inc, South San Francisco, Calif. Third-party writing assistance was provided by Linda Wagner, PharmD, of Envision Pharma Group (Excel Scientific Solutions, Inc), and funded by Genentech, Inc, and Novartis Pharmaceuticals Corporation. |
|
| Disclosure of potential conflict of interest: M. Maurer has consultant arrangements with FAES, Genentech, Inc, Novartis, and Uriach; has received honoraria for lectures from Novartis; has received travel support from Genentech, Inc; has received fees for participation in review activities from Genentech, Inc; has board memberships with Genentech, Inc, Novartis, and Uriach; has received research funding from Novartis to his department; and has received grants from FAES, Novartis, and Uriach. A. Kaplan has performed adjudications of adverse events for Genentech, Inc, Novartis, and Sanofi-Aventis; served on an ad hoc advisory board for CSL Behring; and has consultant arrangements with Genentech, Inc. K. Rosén was employed by and received stock/stock options from Genentech, Inc during the conduct of this study. M. Holden and B. L. Trzaskoma are employed by and receive stock/stock options from Genentech, Inc. A. Iqbal is currently employed by Genentech, Inc, has been employed previously by Pfizer and GlaxoSmithKline, and has received stock/stock options from Genentech, Pfizer, and GlaxoSmithKline. M. Yang is employed by Genentech, Inc. T. B. Casale's university employer has received grants and consulting fees from Genentech, Inc and Novartis. T. B. Casale has received grants from Genentech, Inc and Novartis; has consultant arrangements with Genentech, Inc; and is the Executive Vice President of the American Academy of Allergy, Asthma & Immunology. |
© 2017
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 141 - N° 3
P. 1138 - mars 2018 Retour au numéro
Article précédent
- Autoinflammatory phenotypes in Aicardi-Goutières syndrome with interferon upregulation and serological autoimmune features
- Yuji Sugawara, Kohsuke Imai, Ayako Kashimada, Kengo Moriyama, Shimpei Baba, Ryuta Nishikomori, Mizuho Motegi, Yasuo Takeuchi, Tomohiro Morio
- Ventilation defect percent in helium-3 magnetic resonance imaging as a biomarker of severe outcomes in asthma
- David G. Mummy, Stanley J. Kruger, Wei Zha, Ronald L. Sorkness, Nizar N. Jarjour, Mark L. Schiebler, Loren C. Denlinger, Michael D. Evans, Sean B. Fain
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?